Human genomics in cardiovascular medicine - Implications and perspectives -

Circulation Journal

Volumn 77, Issue 4, 2013, Pages 876-885

  Morita, Hiroyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Clinical application; Genetic variant; Genome wide association study (GWAS); Human genomics

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SMALL INTERFERING RNA;

CARDIOVASCULAR DISEASE; COPY NUMBER VARIATION; CORONARY ARTERY DISEASE; DNA SEQUENCE; EXOME; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOMICS; HEART INFARCTION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MONOGENIC DISORDER; PHENOTYPE; QUANTITATIVE TRAIT LOCUS; REVIEW; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

CARDIOVASCULAR DISEASES; GENETICS, MEDICAL; GENOME, HUMAN; GENOMICS; HUMANS;

EID: 84875533100     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0126     Document Type: Review

References (86)

1. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004; 431: 931-945.
2. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011; 364: 1144-1153.
3. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330: 1041-1046.
4. Post WS, Larson MG, Myers RH, Galderisi M, Levy D. Heritability of left ventricular mass: The Framingham Heart Study. Hypertension 1997; 30: 1025-1028.
5. Lloyd-Jones DM, Nam BH, D'Agostino RB, Levy D, Murabito JM, Wang TJ, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: A prospective study of parents and offspring. JAMA 2004; 291: 2204-2211.
6. Fischer M, Broeckel U, Holmer S, Baessler A, Hengstenberg C, Mayer B, et al. Distinct heritable patterns of angiographic coronary artery disease in families with myocardial infarction. Circulation 2005; 111: 855-862.
7. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061-1073.
8. Ogawa N, Imai Y, Morita H, Nagai R. Genome-wide association study of coronary artery disease. Int J Hypertens 2010; 2010: 790539.
9. International HapMap Consortium. The International HapMap Project. Nature 2003; 426: 789-796.
10. International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299-1320.
11. International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851-861.
12. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 2009; 106: 9362-9367.
13. Wang K, Li M, Hakonarson H. Analysing biological pathways in genome-wide association studies. Nat Rev Genet 2010; 11: 843-854.
14. CARDIoGRAMplusC4D Consortium. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013; 45: 25-33.
15. Helgadottir A, Thorleifsson G, Magnusson KP, Grétarsdottir S, Steinthorsdottir V, Manolescu A, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 2008; 40: 217-224.
16. Jarinova O, Stewart AF, Roberts R, Wells G, Lau P, Naing T, et al. Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol 2009; 29: 1671-1677.
17. Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature 2010; 464: 409-412.
18. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, et al. 9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature 2011; 470: 264-268.
19. Kim JB, Deluna A, Mungrue IN, Vu C, Pouldar D, Civelek M, et al. Effect of 9p21.3 coronary artery disease locus neighboring genes on atherosclerosis in mice. Circulation 2012; 126: 1896-1906.
20. Ioannidis JP. Prediction of cardiovascular disease outcomes and established cardiovascular risk factors by genome-wide association markers. Circ Cardiovasc Genet 2009; 2: 7-15.
21. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: The role of reclassification measures. Ann Intern Med 2009; 150: 795-802.
22. Paynter NP, Chasman DI, Buring JE, Shiffman D, Cook NR, Ridker PM. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med 2009; 150: 65-72.
23. Brautbar A, Ballantyne CM, Lawson K, Nambi V, Chambless L, Folsom AR, et al. Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities study. Circ Cardiovasc Genet 2009; 2: 279-285.
24. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011; 43: 333-338.
25. Myocardial Infarction Genetics Consortium. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009; 41: 334-341.
26. Paynter NP, Chasman DI, Paré G, Buring JE, Cook NR, Miletich JP, et al. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA 2010; 303: 631-637.
27. Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, et al. A multilocus genetic risk score for coronary heart disease: Case-control and prospective cohort analyses. Lancet 2010; 376: 1393-1400.
28. Davies RW, Dandona S, Stewart AF, Chen L, Ellis SG, Tang WH, et al. Improved prediction of cardiovascular disease based on a panel of single nucleotide polymorphisms identified through genome-wide association studies. Circ Cardiovasc Genet 2010; 3: 468-474.
29. Janssens AC, Aulchenko YS, Elefante S, Borsboom GJ, Steyerberg EW, van Duijn CM. Predictive testing for complex diseases using multiple genes: Fact or fiction? Genet Med 2006; 8: 395-400.
30. Ashley EA, Hershberger RE, Caleshu C, Ellinor PT, Garcia JG, Herrington DM, et al. Genetics and cardiovascular disease: A policy statement from the American Heart Association. Circulation 2012; 126: 142-157.
31. Morita H, Nagai R. Family history. N Engl J Med 2005; 352: 732-733.
32. Patel RS, Sun YV, Hartiala J, Veledar E, Su S, Sher S, et al. Association of a genetic risk score with prevalent and incident myocardial infarction in subjects undergoing coronary angiography. Circ Cardiovasc Genet 2012; 5: 441-449.
33. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466: 707-713.
34. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012; 367: 1891-1900.
35. Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS ran domized trial. JAMA 2012; 308: 2497-2506.
36. Musunuru K, Strong A, Frank-Kamenetsky M, Lee NE, Ahfeldt T, Sachs KV, et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 2010; 466: 714-719.
37. Small KS, Hedman AK, Grundberg E, Nica AC, Thorleifsson G, Kong A, et al. Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes. Nat Genet 2011; 43: 561-564.
38. Raychaudhuri S. Mapping rare and common causal alleles for complex human diseases. Cell 2011; 147: 57-69.
39. May D, Blow MJ, Kaplan T, McCulley DJ, Jensen BC, Akiyama JA, et al. Large-scale discovery of enhancers from human heart tissue. Nat Genet 2012; 44: 89-93.
40. Grundberg E, Small KS, Hedman ÅK, Nica AC, Buil A, Keildson S, et al. Mapping cis-and trans-regulatory effects across multiple tissues in twins. Nat Genet 2012; 44: 1084-1089.
41. McCarroll SA, Kuruvilla FG, Korn JM, Cawley S, Nemesh J, Wysoker A, et al. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet 2008; 40: 1166-1174.
42. Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, Zhang Y, et al. Origins and functional impact of copy number variation in the human genome. Nature 2010; 464: 704-712.
43. Wellcome Trust Case Control Consortium. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature 2010; 464: 713-720.
44. Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB. Rare variants create synthetic genome-wide associations. PLoS Biol 2010; 8: e1000294.
45. Bonasio R, Tu S, Reinberg D. Molecular signals of epigenetic states. Science 2010; 330: 612-616.
46. Handy DE, Castro R, Loscalzo J. Epigenetic modifications: Basic mechanisms and role in cardiovascular disease. Circulation 2011; 123: 2145-2156.
47. Shirodkar AV, Marsden PA. Epigenetics in cardiovascular disease. Curr Opin Cardiol 2011; 26: 209-215.
48. Han M, Toli J, Abdellatif M. MicroRNAs in the cardiovascular system. Curr Opin Cardiol 2011; 26: 181-189.
49. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: Approaches and considerations. Nat Rev Genet 2012; 13: 358-369.
50. Zampetaki A, Mayr M. MicroRNAs in vascular and metabolic disease. Circ Res 2012; 110: 508-522.
51. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature 2009; 461: 747-753.
52. Baccarelli A, Rienstra M, Benjamin EJ. Cardiovascular epigenetics: Basic concepts and results from animal and human studies. Circ Cardiovasc Genet 2010; 3: 567-573.
53. Kimura A. Contribution of genetic factors to the pathogenesis of dilated cardiomyopathy: The cause of dilated cardiomyopathy: Genetic or acquired? (Genetic-side). Circ J 2011; 75: 1756-1765.
54. Kubo T, Kitaoka H, Okawa M, Baba Y, Hirota T, Hayato K, et al. Genetic screening and double mutation in Japanese patients with hypertrophic cardiomyopathy. Circ J 2011; 75: 2654-2659.
55. Otsuka H, Arimura T, Abe T, Kawai H, Aizawa Y, Kubo T, et al. Prevalence and distribution of sarcomeric gene mutations in Japanese patients with familial hypertrophic cardiomyopathy. Circ J 2012; 76: 453-461.
56. Morita H, Seidman J, Seidman CE. Genetic causes of human heart failure. J Clin Invest 2005; 115: 518-526.
57. Wang L, Seidman JG, Seidman CE. Narrative review: Harnessing molecular genetics for the diagnosis and management of hypertrophic cardiomyopathy. Ann Intern Med 2010; 152: 513-520.
58. Morita H, Nagai R, Seidman JG, Seidman CE. Sarcomere gene mutations in hypertrophy and heart failure. J Cardiovasc Transl Res 2010; 3: 297-303.
59. Ho CY. Genetics and clinical destiny: Improving care in hypertrophic cardiomyopathy. Circulation 2010; 122: 2430-2440.
60. Seidman CE, Seidman JG. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: A personal history. Circ Res 2011; 108: 743-750.
61. Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. N Engl J Med 2011; 364: 1643-1656.
62. Dietz HC. New therapeutic approaches to Mendelian disorders. N Engl J Med 2010; 363: 852-863.
63. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flügel L, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010; 363: 1397-1409.
64. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011; 471: 225-229.
65. Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011; 471: 230-234.
66. Carvajal-Vergara X, Sevilla A, D'Souza SL, Ang YS, Schaniel C, Lee DF, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010; 465: 808-812.
67. Ge X, Ren Y, Bartulos O, Lee MY, Yue Z, Kim KY, et al. Modeling supravalvular aortic stenosis syndrome with human induced pluripotent stem cells. Circulation 2012; 126: 1695-1704.
68. Kathiresan S, Srivastava D. Genetics of human cardiovascular disease. Cell 2012; 148: 1242-1257.
69. Kryukov GV, Shpunt A, Stamatoyannopoulos JA, Sunyaev SR. Power of deep, all-exon resequencing for discovery of human trait genes. Proc Natl Acad Sci U S A 2009; 106: 3871-3876.
70. Johansen CT, Wang J, Lanktree MB, Cao H, McIntyre AD, Ban MR, et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 2010; 42: 684-687.
71. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004; 305: 869-872.
72. Morita H, Larson MG, Barr SC, Vasan RS, O'Donnell CJ, Hirschhorn JN, et al. Single-gene mutations and increased left ventricular wall thickness in the community: The Framingham Heart Study. Circulation 2006; 113: 2697-2705.
73. Ji W, Foo JN, O'Roak BJ, Zhao H, Larson MG, Simon DB, et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 2008; 40: 592-599.
74. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009; 41: 56-65.
75. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-156.
76. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37: 161-165.
77. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-1272.
78. Kathiresan S; Myocardial Infarction Genetics Consortium. A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction. N Engl J Med 2008; 358: 2299-2300.
79. Falconer DS, Mackay TFC. Introduction to quantitative genetics, 4th edn. 1996.
80. Kryukov GV, Pennacchio LA, Sunyaev SR. Most rare missense alleles are deleterious in humans: Implications for complex disease and association studies. Am J Hum Genet 2007; 80: 727-739.
81. Cooper GM, Shendure J. Needles in stacks of needles: Finding disease-causal variants in a wealth of genomic data. Nat Rev Genet 2011; 12: 628-640.
82. Dewey FE, Pan S, Wheeler MT, Quake SR, Ashley EA. DNA sequencing: Clinical applications of new DNA sequencing technologies. Circulation 2012; 125: 931-944.
83. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011; 43: 491-498.
84. Norton N, Li D, Rieder MJ, Siegfried JD, Rampersaud E, Züchner S, et al. Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. Am J Hum Genet 2011; 88: 273-282.
85. Regalado ES, Guo DC, Villamizar C, Avidan N, Gilchrist D, McGillivray B, et al. Exome sequencing identifies SMAD3 mutations as a cause of familial thoracic aortic aneurysm and dissection with intracranial and other arterial aneurysms. Circ Res 2011; 109: 680-686.
86. Drmanac R, Sparks AB, Callow MJ, Halpern AL, Burns NL, Kermani BG, et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 2010; 327: 78-81.